{
    "nct_id": "NCT06245915",
    "official_title": "An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy of AB-2100 in Patients With Recurrent Advanced or Metastatic Clear-cell Renal Cell Carcinoma (ccRCC)",
    "inclusion_criteria": "* Advanced or metastatic clear-cell renal cell carcinoma\n* Must have received an immune checkpoint inhibitor and a VEGF-targeted therapy in the advanced or metastatic setting. Must have evidence of progression on or after the last treatment regimen or discontinued treatment for unacceptable toxicity.\n* Adequate organ function as per protocol definitions.\n* Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1.\n* Measurable disease at time of enrollment as per protocol definitions.\n* Female subjects of childbearing potential and male subjects must agree to use acceptable method(s) of contraception from enrollment through at least 12 months after AB-2100 infusion.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Any prior systemic RCC therapy within 14 days of time of cell collection (interval of 28 days will be required if the last immediate treatment contained an antibody-based agent).\n* Systemic anti-cancer therapy within 14 days of starting of conditioning chemotherapy (interval of 28 days will be required if the last immediate treatment contained an antibody-based agent)\n* Investigational cellular therapies within 8 weeks prior to start of conditioning chemotherapy\n* Prior treatment with anti-CA9 therapies\n* Myocardial infarction or unstable angina within 6 months prior to screening\n* Pleural effusion that requires drainage for symptom management within 28 days of screening.\n* Active autoimmune disease requiring immunosuppressive therapy or uncontrolled with treatment.\n* Untreated brain metastasis.\n* Subjects unwilling to participate in an extended safety monitoring period.",
    "miscellaneous_criteria": ""
}